ASBPHIGH SIGNALFINANCIAL10-K

ASBP underwent a massive 1-for-40 reverse stock split while experiencing severe financial deterioration with operating losses expanding 15x to $19.4M and total assets collapsing 80%.

The reverse stock split (from 48.9M to 5.0M shares outstanding) is typically a red flag indicating potential delisting concerns and suggests the stock price had fallen dramatically. Combined with exploding losses and asset destruction, this signals a company in severe financial distress that may struggle to continue operations without additional capital.

Comparing 2026-03-30 vs 2025-04-07View on EDGAR →
FINANCIAL ANALYSIS

ASBP's financial position deteriorated catastrophically with total assets plummeting 80% from $6.7M to $1.3M while operating losses exploded from $1.2M to $19.4M. Despite current assets increasing to $1.3M, the company burned through $4.9M in operating cash flow and reduced stockholders' deficit from -$15.6M to -$6.4M primarily through debt reduction. The massive reverse stock split combined with expanding losses, asset destruction, and negative cash flow signals a company in critical financial distress requiring immediate capital infusion to survive.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+2762.4%
$46K→$1.3M

Current assets grew 2762.4% — improving short-term liquidity or inventory/receivables build.

Operating Income
P&L
-1498.1%
-$1.2M→-$19.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
+540%
$144K→$924K

R&D investment increased 540% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
-139.6%
-$2.1M→-$4.9M

Operating cash flow fell 139.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-95.3%
-$12.5M→-$24.5M

Net income declined 95.3% — review whether driven by operations, interest costs, or non-recurring items.

Share Buybacks
Cash Flow
-95.2%
$284.9M→$13.8M

Buyback activity reduced 95.2% — capital being redeployed elsewhere or cash conservation underway.

Total Assets
Balance Sheet
-80.5%
$6.7M→$1.3M

Total assets contracted 80.5% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
+59%
-$15.6M→-$6.4M

Equity base grew 59% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
-51.4%
$15.6M→$7.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-50.8%
$15.6M→$7.7M

Liabilities reduced 50.8% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-04-07
ADDED
The aggregate market value of the voting stock (ordinary shares) held by non-affiliates of the registrant as of the close of business on December 31 2025, the last business day of the registrant s most recently completed fiscal year, was approximately $ 17.4 million based on the closing sale price of the Class A ordinary shares on the Nasdaq Stock Market LLC on that date.
Common stock held by each executive officer, director and by each person known to the registrant who owned 5% or more of its outstanding common stock have been excluded in that such persons may be deemed to be affiliates.
This determination of affiliate status is not necessarily a conclusive determination for other purposes.
As of March 27, 2026, there were 5,024,124 shares of Common Stock, par value $ 0.0001 per share, of the registrant issued and outstanding.
residents; units are to the units sold in our initial public offering, which consisted of one Class A ordinary share and one-half of one redeemable warrant; warrants are to our redeemable warrants sold as part of the units in our initial public offering (whether they were purchased in the initial public offering or thereafter in the open market) and the private placement warrants; and we, us, our, Aspire, Company or our company are to Aspire Biopharma Holdings, Inc.
+7 more — sign up free →
REMOVED
As of Apil 7, 2025, there were 48,900,970 shares of Common Stock, par value $ 0.0001 per share, of the registrant issued and outstanding.
5 Manufacturing We currently contract with third parties for the manufacture of our product candidates for preclinical studies and clinical trials and intend to do so in the future.
We have entered into a development and manufacturing agreement with a contract manufacturer, Glatt, in the fourth quarter of 2024 to produce sufficient quantities of our high-dose sublingual aspirin product (sometimes referred to informally herein as Instaprin for ease of reference) for our clinical trials required to obtain FDA approval to market the product and complete clinical trials.
While we believe that Glatt is capable of producing the drug product to support our aspirin product development plan, including our planned clinical trials, we believe there are a number of alternative third-party manufacturers that have similar capabilities and would be capable of providing sufficient quantities of drug product for our aspirin development plan.
We believe that both Glatt and the fill-and-finish contract manufacturer are compliant under current good manufacturing practice, or cGMP, requirements and have experience with cGMP inspections of their respective facilities.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →